Biblio

Author Title [ Type

] Year

Filters: Author is Andreeff, Michael [Clear All Filters]

Journal Article

Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera M-E, et al. CL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013.

Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, Dinardo CD, Verstovsek S, Andreeff M, Kadia TM, et al. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020;4(8):1690-1699.

Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, et al. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2015.

Carter BZ, Mak PYee, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13(1):57.

Carter BZ, Mak PYee Yee, Muftuoglu M, Tao W, Baozhen K, Jiang P, Bedoy AD, Ostermann LB, Nishida Y, Isqandarova S, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023.

Saito K, Zhang Q, Yang H, Yamatani K, Ai T, Ruvolo V, Baran N, Cai T, Ma H, Jacamo R, et al. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition. Blood Adv. 2021.

Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, et al. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019;3(22):3661-3673.

Carter BZ, Mak PYee, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, et al. Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther. 2022.

Pourebrahim R, Montoya RHeinz, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis. 2023;14(6):371.

Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes. Exp Hematol. 2016.

Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. Int J Hematol. 2024.

Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, et al. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021.

Borthakur G, Zeng Z, Cortes JE, Chen H-C, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, et al. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020.

Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, Dinardo CD, Sasaki K, Issa GC, et al. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022:JCO2102823.

Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014.

Kornblau SM, Qutub A, Yao H, York H, Qiu YHua, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, et al. Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS One. 2013;8(10):e78453.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo R, Borthakur G, Cortes JE, Ravandi-Kashani F, Ramachandran A, Andreeff M. Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clin Cancer Res. 2014.

Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015.

Carter BZ, Mak PYee, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, et al. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015.

Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood. 2022.